Shares in VistaGen Therapeutics have plummeted after the company reported that its lead pherine nasal spray candidate failed the first of two phase 3 trials in social anxiety disorder (SAD ...

VistaGen Therapeutics Inc . (NASDAQ:VTGN) reported a net loss of $14.1 million for the third quarter of fiscal year 2025, compared to a net loss of $6.4 million in the same period last year.

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.66 per share a year ago.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company ...

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In an ever-expanding field, firms are racing to attract new talent – just as a major shortage of stockbrokers looms. 2025 has been a rocky year so far for equity investors, but how you respond ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Vistagen Therapeutics Inc (VTGN) reports positive Phase 3 trial outcomes and financial stability, despite rising operational costs and market competition. SOUTH SAN FRANCISCO, Calif., February 13, ...